Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has been given an average rating of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $31.00.

A number of equities research analysts have recently commented on MPLT shares. Leerink Partners started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “outperform” rating and a $30.00 price objective on the stock. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 target price on the stock. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price target on the stock.

Maplight Therapeutics Price Performance

NASDAQ MPLT opened at $16.80 on Thursday. The stock has a market cap of $762.27 million and a price-to-earnings ratio of -0.45. The company’s 50-day moving average is $17.88. Maplight Therapeutics has a fifty-two week low of $12.24 and a fifty-two week high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last posted its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Insider Transactions at Maplight Therapeutics

In related news, Director Robert C. Malenka sold 7,039 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.02, for a total value of $126,842.78. Following the completion of the sale, the director owned 358,234 shares of the company’s stock, valued at approximately $6,455,376.68. The trade was a 1.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 41,438 shares of company stock valued at $762,687.

Institutional Trading of Maplight Therapeutics

A hedge fund recently bought a new stake in Maplight Therapeutics stock. Strs Ohio acquired a new stake in Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,000 shares of the company’s stock, valued at approximately $53,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.